ALN-KHK
ALN-KHK-001
Phase 2 small_molecule terminated
Quick answer
ALN-KHK for Type 2 Diabetes Mellitus (T2DM) is a Phase 2 program (small_molecule) at ALNYLAM PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ALNYLAM PHARMACEUTICALS, INC.
- Indication
- Type 2 Diabetes Mellitus (T2DM)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated